Brief: Arcutis Biotherapeutics Says Majority Of Individuals With Co's Atopic Dermatitis Improved Roflumilast Cream 0.15%

Arcutis Biotherapeutics

14/01/2024 10:41

Jan 14 (Reuters) - Arcutis Biotherapeutics Inc  ARQT.O :
    * MAJORITY OF INDIVIDUALS WITH ATOPIC DERMATITIS IMPROVED
ROFLUMILAST CREAM 0.15% ACCORDING TO NEW DATA FROM PHASE 3
PROGRAM
    * DATA HIGHLIGHT 91.5% OF INDIVIDUALS TREATED WITH
ROFLUMILAST
CREAM HAD MEASURABLE IMPROVEMENT IN ECZEMA AREA AND SEVERITY
INDEX IN 4 WEEKS
    * ROFLUMILAST CREAM 0.15% SAFETY AND TOLERABILITY DATA WERE
COMPARABLE WITH VEHICLE, WITH LOW RATES OF APPLICATION SITE
ADVERSE EVENTS

Source text for Eikon:  ID:nGNX5MdMq5 
Further company coverage:  ARQT.O 

 ((Reuters.Briefs@thomsonreuters.com;))